ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

10:00AM-10:50AM: Abstract Number: 2043

Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2043–2047)

10:00AM-10:50AM: Abstract Number: 1997

Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results

RA – Treatments I: Maximizing Health in RA (1993–1997)

10:00AM-10:50AM: Abstract Number: 1995

Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study

RA – Treatments I: Maximizing Health in RA (1993–1997)

10:00AM-10:50AM: Abstract Number: 1958

Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events

Health Services Research (1958–1962)

10:00AM-10:50AM: Abstract Number: 1987

Predictors of Adverse Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus Transitioning to Adult Care

Pediatric Rheumatology – Clinical II: Outcomes & Care Delivery (1983–1987)

10:00AM-10:50AM: Abstract Number: 2045

Resident Memory T Cells in Synovial Tissue Mediate Arthritis Flares

T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2043–2047)

10:00AM-10:50AM: Abstract Number: 1994

Rheumatoid Arthritis Improvement After Exposure to an Anti-Inflammatory “ITIS” Diet Is Associated with Changes of Gut Microbiome and Systemic Metabolome

RA – Treatments I: Maximizing Health in RA (1993–1997)

10:00AM-10:50AM: Abstract Number: 2047

Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential

T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2043–2047)

10:00AM-10:50AM: Abstract Number: 1983

Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Pediatric Rheumatology – Clinical II: Outcomes & Care Delivery (1983–1987)

10:00AM-10:50AM: Abstract Number: 1962

Utilization of Telehealth Among Patients with Rheumatic Diseases in the Early Months of the COVID-19 Pandemic

Health Services Research (1958–1962)

10:00AM-10:50AM: Abstract Number: 1985

Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical II: Outcomes & Care Delivery (1983–1987)

11:00AM-11:50AM: Abstract Number: 1991

Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma

Pediatric Rheumatology – Clinical III: Systemic Autoimmune Disease (1988–1992)

11:00AM-11:50AM: Abstract Number: 2050

Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate

Vasculitis – ANCA-Associated (2048–2052)

11:00AM-11:50AM: Abstract Number: 2048

Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis

Vasculitis – ANCA-Associated (2048–2052)

11:00AM-11:50AM: Abstract Number: 2024

Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].